At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMVT Immunovant, Inc.
Post-Mkt 07-02 18:43:00 EDT
38.79
+0.65
+1.70%
盘后38.80
+0.01+0.03%
18:30 EDT
High38.85Low37.75Vol1.05M
Open38.48D1 Closing38.14Amplitude2.88%
Mkt Cap7.96BTradable Cap3.45BTotal Shares205.31M
T/O40.28MT/O Rate1.18%Tradable Shares89.02M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Chief Technology Officer Of Immunovant Sold 53% Of Their Shares
Simply Wall St.  ·  07-02 23:48
Chief Technology Officer Of Immunovant Sold 53% Of Their Shares
Immunovant is Maintained at Buy by Citigroup
Dow Jones  ·  07-01 02:59
Immunovant is Maintained at Buy by Citigroup
Immunovant price target raised to $61 from $57 at Citi
TIPRANKS  ·  06-30 18:40
Immunovant price target raised to $61 from $57 at Citi
Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015
Reuters  ·  06-27
Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015
Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million
Reuters  ·  06-27
Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million
S&P 500 Futures Drop in Premarket Trading; on Semiconductor, Davita Lag
Dow Jones  ·  06-26
S&P 500 Futures Drop in Premarket Trading; on Semiconductor, Davita Lag
Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed
Simply Wall St.  ·  06-19
Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed
Immunovant director Atul Pande disposes of USD 51,030 common shares
Reuters  ·  06-17
Immunovant director Atul Pande disposes of USD 51,030 common shares
A Look At Immunovant (IMVT) Valuation As IMVT 1402 Trial Engagement Lifts Investor Interest
Simply Wall St.  ·  06-11
A Look At Immunovant (IMVT) Valuation As IMVT 1402 Trial Engagement Lifts Investor Interest
Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?
Simply Wall St.  ·  06-08
Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?
Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million
Reuters  ·  05-30
Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million
Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum
Simply Wall St.  ·  05-30
Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum
Immunovant Is Maintained at Buy by Guggenheim
Dow Jones  ·  05-26
Immunovant Is Maintained at Buy by Guggenheim
H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)
TIPRANKS  ·  05-26
H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)
Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million
Reuters  ·  05-23
Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million
Immunovant Is Maintained at Hold by Truist Securities
Dow Jones  ·  05-22
Immunovant Is Maintained at Hold by Truist Securities
Immunovant price target raised to $30 from $23 at Truist
TIPRANKS  ·  05-22
Immunovant price target raised to $30 from $23 at Truist
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications
TIPRANKS  ·  05-22
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Benzinga  ·  05-22
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Immunovant (IMVT) and Anteris Technologies Global Corp. (AVR)
TIPRANKS  ·  05-21
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Immunovant (IMVT) and Anteris Technologies Global Corp. (AVR)

Introduction

Company Name.
Immunovant, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Issue price:
--